The U.S. Food and Drug Administration has approved Zurzuvae (zuranolone), an oral medication to treat postpartum depression (PPD) in adults. PPD is a serious condition that can lead to feelings of sadness, guilt, and even thoughts of self-harm. Until now, treatment for PPD was limited to IV injections given in healthcare facilities. The availability of an oral medication provides a beneficial option for women coping with these extreme emotions. The efficacy of Zurzuvae was demonstrated in clinical studies, with patients showing significant improvement in symptoms compared to those on a placebo. However, it is important to note that Zurzuvae can impair a person’s ability to drive or operate machinery and may cause side effects such as drowsiness and dizziness. It may also cause fetal harm, so women should use effective contraception while taking it. The recommended dose is 50mg taken once daily for 14 days with a fatty meal. Overall, this approval provides a new treatment option for women experiencing postpartum depression.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-postpartum-depression